Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Added

TDQS

A4.6/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already indicate readOnlyHint=true, idempotentHint=true, and destructiveHint=false. The description adds key behavioral details: for company type it pulls financial data from SEC EDGAR/XBRL with off-calendar year handling, for drug type it pulls FAERS and FDA data. It also mentions results are sorted by primary metric and returns citation URIs. No contradiction with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is a single paragraph but effectively structured: starting with user query examples, then stating purpose, then detailing type-specific behavior. It's slightly long but every sentence adds value. Could be slightly more concise but still very good.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given the tool's complexity (two entity types, financial and drug data, sorting, citation URIs), the description covers essential aspects. It mentions return format (paired data + URIs) but doesn't detail exact output structure. However, annotations and schema compensate. A brief note on rate limits or pagination would improve completeness.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100% but the description adds significant value: it provides example inputs (e.g., 'AAPL','MSFT'), explains what each type does, and clarifies constraints (2-5 values). This goes well beyond the schema's brief descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description starts with explicit user queries ('Compare X and Y', 'X vs Y', 'which is bigger') and states the tool provides side-by-side comparison of 2-5 companies or drugs. It clearly distinguishes itself from sequential lookups by saying 'ALWAYS PREFER over sequential single-pack lookups'. The verb 'compare' and resource 'entities' are unambiguous.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says to prefer this tool over sequential lookups when comparing entities. It also explains what each type returns (company vs drug). It doesn't explicitly state when not to use it, but the context is clear.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A4.1/5.0
Disambiguation4/5

Most tools have distinct purposes, especially within the Polymarket and data query groups. However, the three ask_pipeworx variants (ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded) and the overlap between deep_research and ask_pipeworx for broader questions could cause minor confusion.

Naming Consistency3/5

Tool names follow some consistent prefixes (ask_pipeworx, polymarket_, scan_, recent_) but overall mix verb_noun, noun phrases, and standalone verbs (forget, recall, remember). This inconsistency reduces predictability, though the patterns are still readable.

Tool Count3/5

32 tools is high but justifiable given the server's dual role as a Pipeworx data gateway and Polymarket analysis suite. Each tool serves a distinct function in the workflow, but the count borders on heavy and could be streamlined.

Completeness4/5

The tool set covers the full lifecycle for the server's domain: discovery, querying, grounded answers, entity resolution, company profiles, fact-checking, prediction market analysis, memory, and monitoring. Minor gaps exist (no account management or direct data modification), but these are out of scope for a read-only data interface.